Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 pandemic.

Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the rapidly-spreading COVID-19 pandemic, through the development of a possible preventive vaccine candidate against SARS-CoV-2.

• J&J has selected a lead COVID-19 vaccine candidate; the Company anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021.
• The company has collaborated with Emergent BioSolutions, Inc. to support the manufacturing of the lead investigational vaccine candidate. This agreement was designed to further the goal of supplying more than one billion doses of the vaccine worldwide.
• The search for a vaccine relies on partnerships—including collaborations between the Janssen Pharmaceutical Companies of J&J, Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health & Human Services, and the Beth Israel Deaconess Medical Center (BIDMC).
• These are the same technologies that were used in the development and manufacturing of Janssen’s investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company’s Zika, RSV and HIV vaccine candidates.

Source: Our Efforts to Develop a Vaccine and Identify Therapies for COVID-19. Content Lab U.S. https://www.jnj.com/coronavirus/prevention-and-treatment. Published 2020. Accessed May 12, 2020.

For Complete details pls visit: https://www.jnj.com/coronavirus/prevention-and-treatment